Compare Charles River Laboratories Intl. Inc (CRL) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Global X SuperDividend ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $231.94 (market cap $11.14B), while Global X SuperDividend ETF trades at $24.82. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| CRL | SDIV | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $233.60 | $26.34 |
52-Week Low | $145.57 | $22.90 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
SDIV trades at $24.52, down 0.33% today, with a neutral technical signal overall. The ETF maintains a consistent dividend payout of $0.18 per share, with recent distributions in May and June 2026. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance cluster around $24-$25. Recent news highlights SDIV's appeal for income investors seeking diversification from tech-heavy portfolios.
SDIV offers investors exposure to high-yield global equities with minimal technology exposure, providing diversification benefits. The 9.29% yield remains attractive for income-focused portfolios, though the fund's heavy weighting in financials and energy sectors introduces sector concentration risks. Current technical positioning suggests limited near-term price movement potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
